Imaging with Positron-Emitting Taxanes, Camptothecins, and Other Drugs as a Guide to Antitumor Therapy
Description of Invention:
Available for licensing and commercial development is a method for using of positron-emitting compounds to label taxane type drugs. This invention also relates to the use, synthesis and structure of three radio-labeled probe molecules, 11C-SN-38, 11C-imatinib, and 11C-mitoxantrone. SN-38 is a major active metabolite of Camptosar, a product marketed by Pharmacia for the treatment of colorectal cancer. Imatinib is a compound that is used to treat chronic myeloid leukemia (CML) and is marketed under the tradename Gleevec. Mitoxantrone is also used to treat certain types of cancers and multiple sclerosis. For all of these compounds the FDA approved new and expanded uses and there is intense interest in determining whether and where each of the compounds actually collects in the body, and especially whether they are taken up by the targeted tumor. Traditional approaches to determine drug uptake and retention have been invasive. Advantages of using this technology include: 1) avoidance of exposing patients to toxic drugs that have no potential for benefit; 2) ability to rapidly determine whether a given tumor will be likely to respond to a particular drug; and 3) the ability to monitor the impact of various dosages, schedules, and modulators for delivery, in situ, at the actual tumor under treatment conditions. Further, methods to guide treatment of solid tumors, with labeled taxanes, are also disclosed in the present application.
Inventors:
Jerry M. Collins (FDA) Raymond W. Klecker (FDA) Lawrence Anderson (FDA)
Patent Status:
DHHS Reference No. E-263-1998/0 --
U.S. Provisional Application No. 60/155,061 filed 21 Sep 1999
U.S. Patent Application No. 10/088,561 filed 19 Mar 2002
DHHS Reference No. E-263-1998/1 --
U.S. Patent Application No. 10/319,812 filed 16 Dec 2002
Relevant Publication:
Additional information may be found in: Ravert et al., "Radiosynthesis of [11C]paclitaxel," J Label Compd and Radiopharm, 2002, 45(6):471-477.
Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
For Additional Information Please Contact: Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220
